Omadacycline: A Review of the Clinical Pharmacokinetics and Pharmacodynamics

Rodvold, Keith A.; Burgos, Rodrigo M; Tan, Xing; Pai, Manjunath P.

doi:10.1007/s40262-019-00843-4

Cited by 35 publications

(20 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the pharmacokinetic study of Rodvold et al, omadacycline exhibited unsatisfactory in vivo availability, a single oral dose of 300 mg or intravenous injection dose of 100 mg of omadacycline resulted in a maximum plasma concentration of approximately 0.5–0.6 mg/L. 32 Considering the difficult availability and high price of omadacycline, it is not suggested as a candidate drug to treat the gonococcal infection.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of Neisseria gonorrhoeae Isolates Susceptibility to Tetracycline Antibiotics from 9 Provinces in China Since 2020

Zhou¹,

Xu²,

Zhu³

et al. 2022

IDR

View full text Add to dashboard Cite

Purpose The increasing drug resistance of Neisseria gonorrhoeae has become a serious public health concern. This study investigated N. gonorrhoeae isolates susceptibility to tetracycline antibiotics and the correlation between minimum inhibitory concentrations (MICs) of different antibiotics. The presence of resistance determinants in N. gonorrhoeae strains displaying different levels of tigecycline resistance was also compared. Methods The minimum inhibitory concentrations (MICs) of tetracycline, minocycline, tigecycline, eravacycline, omadacycline on 412 N. gonorrhoeae isolates were measured by the agar dilution method. The MICs of ceftriaxone and azithromycin were also measured to determine the correlations between antibiotics by the value of the correlation coefficient R . The presence of resistance determinants was identified through polymerase chain reaction (PCR) and sequencing. Results The MIC 90 was 64mg/L for tetracycline, 64mg/L for minocycline, 0.5mg/L for tigecycline, 0.5mg/L for eravacycline, 4mg/L for omadacycline, 0.25 mg/L for ceftriaxone, and 1mg/L for azithromycin. The MIC 90 and mode of tigecycline and eravacycline were much lower than those of tetracycline and minocycline. A poor correlation between omadacycline, eravacycline and tetracycline susceptibility was observed. Minocycline has a strong correlation with tetracycline. PorB1 typing, TetM -encoding plasmid, and mtrR promoter adenine deletion were significantly correlated with tigecycline MIC > 0.25mg/L. Conclusion This study suggested that tigecycline and eravacycline had better in vitro activity and might be alternative antibiotics against resistant N. gonorrhoeae infections. Nevertheless, further in vitro experiments and clinical studies are needed for verification.

show abstract

Section: Discussionmentioning

confidence: 99%

Evaluation of Neisseria gonorrhoeae Isolates Susceptibility to Tetracycline Antibiotics from 9 Provinces in China Since 2020

Zhou¹,

Xu²,

Zhu³

et al. 2022

IDR

View full text Add to dashboard Cite

show abstract

“…The C9 and C7 sites of the D ring of the tetracycline core are chemically modified to stabilize the exhaust pump and ribosomal protective protein mechanism of tetracycline resistance. 69 Similar to other tetracyclines, omadacycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. Omadacycline provides a promising treatment plan for ABSSSI and community-acquired bacterial pneumonia (CABP).…”

Section: Progress In Research and Development Of Drugs Against Drug-resistant Bacteriamentioning

confidence: 99%

Development and Research Progress of Anti-Drug Resistant Bacteria Drugs

Cui¹,

Lü²,

Yue³

2021

IDR

View full text Add to dashboard Cite

Bacterial resistance has become increasingly serious because of the widespread use and abuse of antibiotics. In particular, the emergence of multidrug-resistant bacteria has posed a serious threat to human public health and attracted the attention of the World Health Organization (WHO) and the governments of various countries. Therefore, the establishment of measures against bacterial resistance and the discovery of new antibacterial drugs are increasingly urgent to better contain the emergence of bacterial resistance and provide a reference for the development of new antibacterial drugs. In this review, we discuss some antibiotic drugs that have been approved for clinical use and a partial summary of the meaningful research results of anti-drug resistant bacterial drugs in different fields, including the antibiotic drugs approved by the FDA from 2015 to 2020, the potential drugs against drug-resistant bacteria, the new molecules synthesized by chemical modification, combination therapy, drug repurposing, immunotherapy and other therapies.

show abstract

“…51,55,56 Furthermore, all three agents concentrate well in the skin and surrounding soft tissues. 44,45 Limited in vitro and in vivo pharmacokinetic/pharmacodynamic (PK/PD) data are available for doxycycline and minocycline. 44 In a hollow fiber infection model of MRSA simulating free drug serum concentrations of oral minocycline 200 mg/day, a −1.8 −0.2 log reduction in count by 24 h was observed.…”

Section: Pharmacokinetics and Pharmacodynamicsmentioning

confidence: 99%

“…Using the median AUC0-24/MIC ratio targets identified in this study and the population-predicted AUCs in patients at near steady-state conditions, 45 standard oral dosing of omadacycline is expected to result in exposures associated with net stasis-1-log10 killing against most S. aureus strains with MIC values ≤0.5 mg/L (current FDA breakpoint).…”

Section: Pharmacokinetics and Pharmacodynamicsmentioning

confidence: 99%

Use of oral tetracyclines in the treatment of adult outpatients with skin and skin structure infections: Focus on doxycycline, minocycline, and omadacycline

Bidell

Lodise

2021

Pharmacotherapy

View full text Add to dashboard Cite

Skin and soft tissue infections (SSTIs), or acute bacterial skin and skin structure infections (ABSSSIs), are among the most common indications for outpatient antibiotic prescriptions in the USA. 1,2 To guide treatment decisions, the Infectious Diseases Society of America (IDSA) skin and soft tissue guideline from 2014 recommends characterizing SSTIs as either non-purulent or purulent. 3 This approach is particularly important in outpatient settings where treatment is often empiric, and therefore, agents should be selected to target suspected pathogens. Cellulitis and erysipelas are the most common non-purulent SSTIs and are caused in most cases by streptococci. Guideline-concordant outpatient oral antibiotics for treating common non-purulent SSTIs include penicillin VK, cephalosporins, dicloxacillin, and clindamycin. In contrast, purulent infections are commonly caused by Staphylococcus aureus, and the presence of methicillin-resistant S. aureus (MRSA) is often of clinical concern.Oral agents with MRSA activity that are recommended by IDSA

show abstract

Omadacycline: A Review of the Clinical Pharmacokinetics and Pharmacodynamics

Cited by 35 publications

References 62 publications

Evaluation of Neisseria gonorrhoeae Isolates Susceptibility to Tetracycline Antibiotics from 9 Provinces in China Since 2020

Evaluation of Neisseria gonorrhoeae Isolates Susceptibility to Tetracycline Antibiotics from 9 Provinces in China Since 2020

Development and Research Progress of Anti-Drug Resistant Bacteria Drugs

Use of oral tetracyclines in the treatment of adult outpatients with skin and skin structure infections: Focus on doxycycline, minocycline, and omadacycline

Contact Info

Product

Resources

About